Medartis Holding AG (MED) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Medartis Holding AG (MED) has a cash flow conversion efficiency ratio of 0.088x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CHF24.17 Million ≈ $30.56 Million USD) by net assets (CHF275.87 Million ≈ $348.78 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Medartis Holding AG stock valuation for the company's overall valuation and market capitalisation.
Medartis Holding AG - Cash Flow Conversion Efficiency Trend (2015–2025)
This chart illustrates how Medartis Holding AG's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Medartis Holding AG Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Medartis Holding AG ranked by their cash flow conversion efficiency. Explore MED cash flow quality score to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Cansino Biologics Inc
SHG:688185
|
0.003x |
|
AS LHV GROUP EO -10
F:ASU0
|
-1.381x |
|
Cangzhou Mingzhu Plastic Co Ltd
SHE:002108
|
-0.008x |
|
Boai NKY Pharmaceuticals Ltd
SHE:300109
|
0.038x |
|
Jiangsu Zongyi Co Ltd
SHG:600770
|
0.009x |
|
Changsha DIALINE New Material Sci & Tech Co Ltd
SHE:300700
|
-0.041x |
|
Sinar Mas Agro Resources and Technology Tbk PT
JK:SMAR
|
0.103x |
|
SK Reit Co Ltd
KO:395400
|
N/A |
Annual Cash Flow Conversion Efficiency for Medartis Holding AG (2015–2025)
The table below shows the annual cash flow conversion efficiency of Medartis Holding AG from 2015 to 2025. View today's stock price for Medartis Holding AG for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | CHF275.87 Million ≈ $348.78 Million |
CHF34.82 Million ≈ $44.02 Million |
0.126x | +6.11% |
| 2024-12-31 | CHF269.65 Million ≈ $340.91 Million |
CHF32.07 Million ≈ $40.55 Million |
0.119x | +51.78% |
| 2023-12-31 | CHF254.96 Million ≈ $322.34 Million |
CHF19.98 Million ≈ $25.26 Million |
0.078x | +574.45% |
| 2022-12-31 | CHF237.78 Million ≈ $300.62 Million |
CHF-3.93 Million ≈ $-4.97 Million |
-0.017x | -117.66% |
| 2021-12-31 | CHF224.00 Million ≈ $283.19 Million |
CHF20.95 Million ≈ $26.49 Million |
0.094x | +58.02% |
| 2020-12-31 | CHF213.04 Million ≈ $269.33 Million |
CHF12.61 Million ≈ $15.94 Million |
0.059x | +57.27% |
| 2019-12-31 | CHF215.57 Million ≈ $272.54 Million |
CHF8.11 Million ≈ $10.26 Million |
0.038x | +27.36% |
| 2018-12-31 | CHF218.23 Million ≈ $275.91 Million |
CHF6.45 Million ≈ $8.15 Million |
0.030x | -95.43% |
| 2017-12-31 | CHF17.04 Million ≈ $21.54 Million |
CHF11.01 Million ≈ $13.92 Million |
0.646x | -7.16% |
| 2016-12-31 | CHF17.10 Million ≈ $21.62 Million |
CHF11.91 Million ≈ $15.06 Million |
0.696x | +375.23% |
| 2015-12-31 | CHF-46.95 Million ≈ $-59.36 Million |
CHF11.88 Million ≈ $15.02 Million |
-0.253x | -- |
About Medartis Holding AG
Medartis Holding AG, a medical device company, engages in the development, manufacturing, and sales of implant solutions worldwide. The company's medical devices are used for the treatment of surgical fixation of bone fractures for upper and lower extremities, as well as for the cranio-maxillofacial surgery. It provides products for the hand, wrist, forearm, elbow, shoulder, and foot and ankle, a… Read more